Skeletal actions of fasting-induced adipose factor (FIAF)

Endocrinology

Volumn 154, Issue 12, 2013, Pages 4685-4694

  Lin, Jian Ming ^a   Naot, Dorit ^a   Watson, Maureen ^a   Costa, Jessica L ^a   Reid, Ian R ^a   Cornish, Jillian ^a   Grey, Andrew ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; COLONY STIMULATING FACTOR 1; CONNECTIVE TISSUE GROWTH FACTOR; DENDRITIC CELL SPECIFIC TRANSMEMBRANE PROTEIN; FASTING INDUCED ADIPOSE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT C1; UNCLASSIFIED DRUG; ANGIOPOIETIN; ANGPTL4 PROTEIN, MOUSE; DC-STAMP PROTEIN, MOUSE; NERVE PROTEIN; NFATC1 PROTEIN, MOUSE;

ADIPOSE TISSUE; ANIMAL CELL; ARTICLE; BONE MARROW CELL; BONE MARROW CULTURE; BONE METABOLISM; CELL ASSAY; CELL CULTURE; CELL DIFFERENTIATION; CELL ISOLATION; CELL MATURATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION; MALE; MITOGENESIS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA CELL; ANIMAL; CELL LINE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MACROPHAGE; METABOLISM; PHYSIOLOGY; TIME;

ANGIOPOIETINS; ANIMALS; BONE MARROW CELLS; CELL LINE; GENE EXPRESSION REGULATION; MACROPHAGES; MEMBRANE PROTEINS; MICE; NERVE TISSUE PROTEINS; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; TIME FACTORS;

EID: 84888209692     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1238     Document Type: Article

References (55)

1. Li C. Genetics and regulation of angiopoietin-like proteins 3 and 4. Curr Opin Lipidol 2006;17:152-156.
2. Kersten S, Mandard S, Tan NS, et al. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem. 2000;275:28488-28493.
3. Yoon JC, Chickering TW, Rosen ED, et al. Peroxisome proliferator- activated receptor γ target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol Cell Biol. 2000;20:5343-5349.
4. Zhu P, Goh YY, Chin HF, Kersten S, Tan NS. Angiopoietin-like 4: a decade of research. Biosci Rep. 2012;32:211-219.
5. Ge H, Yang G, Huang L, Motola DL, Pourbahrami T, Li C. Olig-omerization and regulated proteolytic processing of angiopoietin-like protein 4. J Biol Chem. 2004;279:2038-2045.
6. Xu A, Lam MC, Chan KW, et al. Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc Natl Acad Sci USA. 2005;102:6086-6091.
7. Mattijssen F, Kersten S. Regulation of triglyceride metabolism by angiopoietin-like proteins. Biochim Biophys Acta. 2012;1821:782-789.
8. Mandard S, Zandbergen F, van Straten E, et al. The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity-.[published correction appears in J Biol Chem. 2006;281(30):21575]. J Biol Chem. 2006;281:934-944.
9. Ito Y, Oike Y, Yasunaga K, et al. Inhibition of angiogenesis and vascular leakiness by angiopoietin-related protein 4. Cancer Res. 2003;63:6651-6657.
10. Galaup A, Cazes A, Le Jan S, et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci USA. 2006;103:18721-18726.
11. Zhu H, Li J, Qin W, et al. [Cloning of a novel gene, ANGPTL4 and the functional study in angiogenesis]. Chung Hua I Hsueh Tsa Chih 2002;82:94-99.
12. Hermann LM, Pinkerton M, Jennings K, et al. Angiopoietin-like-4 is a potential angiogenic mediator in arthritis. Clin Immunol. 2005;115:93-101.
13. Sukonina V, Lookene A, Olivecrona T, Olivecrona G. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc Natl Acad Sci USA. 2006;103:17450-17455.
14. Yau MH, Wang Y, Lam KS, Zhang J, Wu D, Xu A. A highly conserved motif within the NH2-terminal coiled-coil domain of angio-poietin- like protein 4 confers its inhibitory effects on lipoprotein lipase by disrupting the enzyme dimerization. J Biol Chem. 2009;284:11942-11952.
15. Chomel C, Cazes A, Faye C, et al. Interaction of the coiled-coil domain with glycosaminoglycans protects angiopoietin-like 4 from proteolysis and regulates its antiangiogenic activity. Faseb J. 2009; 23:940-949.
16. Yang YH, Wang Y, Lam KS, et al. Suppression of the Raf/MEK/ERK signaling cascade and inhibition of angiogenesis by the carboxyl terminus of angiopoietin-like protein 4. Arterioscler Thromb Vasc Biol. 2008;28:835-840.
17. Clark EM, Ness AR, Tobias JH. Adipose tissue stimulates bone growth in prepubertal children. J Clin Endocrinol Metab. 2006;91:2534-2541.
18. Di Monaco M, Vallero F, Di Monaco R, Tappero R, Cavanna A. Skeletal muscle mass, fat mass, and hip bone mineral density in elderly women with hip fracture. J Bone Miner Metab. 2007;25:237-242.
19. Reid IR. Fat and bone. Arch Biochem Biophys. 2010;503:20-27.
20. Reid IR, Plank LD, Evans MC. Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. J Clin Endocrinol Metab. 1992;75:779-782.
21. Dawson-Hughes B, Shipp C, Sadowski L, Dallal G. Bone density of the radius, spine, and hip in relation to percent of ideal body weight in postmenopausal women. Calcif Tissue Int. 1987;40:310-314.
22. Ribot C, Tremollieres F, Pouilles JM, Bonneu M, Germain F, Louvet JP. Obesity and postmenopausal bone loss: the influence of obesity on vertebral density and bone turnover in postmenopausal women. Bone. 1987;8:327-331.
23. Reid IR, Ames R, Evans MC, et al. Determinants of total body and regional bone mineral density in normal postmenopausal women-a key role for fat mass. J Clin Endocrinol Metab. 1992;75:45-51.
24. Williams GA, Wang Y, Callon KE, et al. In vitro and in vivo effects of adiponectin on bone. Endocrinology. 2009;150:3603-3610.
25. Lee HW, Kim SY, Kim AY, Lee EJ, Choi JY, Kim JB. Adiponectin stimulates osteoblast differentiation through induction of COX2 in mesenchymal progenitor cells. Stem Cells. 2009;27:2254-2262.
26. Tu Q, Zhang J, Dong LQ, et al. Adiponectin inhibits osteoclastogenesis and bone resorption via APPL1-mediated suppression of Akt1. J Biol Chem. 2011;286:12542-12553.
27. Luo XH, Guo LJ, Yuan LQ, et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via theMAPKsignaling pathway. Exp Cell Res. 2005;309:99-109.
28. Luo XH, Guo LJ, Xie H, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res. 2006;21:1648-1656.
29. Cornish J, Callon KE, Bava U, et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol. 2002;175:405-415.
30. Pasco JA, Henry MJ, Kotowicz MA, et al. Serum leptin levels are associated with bone mass in nonobese women. J Clin Endocrinol Metab. 2001;86:1884-1887.
31. Thomas T, Burguera B. Is leptin the link between fat and bone mass? J Bone Miner Res. 2002;17:1563-1569.
32. Karsenty G, Oury F. The central regulation of bone mass, the first link between bone remodeling and energy metabolism. J Clin Endocrinol Metab. 2010;95:4795-4801.
33. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3:889-901.
34. Yagi M, Miyamoto T, Sawatani Y, et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J ExpMed. 2005;202:345-351.
35. Cornish J, Callon KE, Bava U, Kamona SA, Cooper GJ, Reid IR. Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. Bone. 2001;29:162-168.
36. Lin JM, Callon KE, Lin JS, et al. Actions of fibroblast growth factor-8 in bone cells in vitro. Am J Physiol Endocrinol Metab. 2009;297:E142-E150.
37. Lin JM, Callon KE, Lin CQ, et al. Alteration of bone cell function by RANKL and OPG in different in vitro models. Eur J Clin Invest. 2007;37:407-415.
38. Cornish J, Callon KE, Naot D, et al. Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. Endocrinology. 2004;145:4366-4374.
39. O'Sullivan S, Naot D, Callon K, et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res. 2007;22:1679-1689.
40. Hattersley G, Owens J, Flanagan AM, Chambers TJ. Macrophage colony stimulating factor (M-CSF) is essential for osteoclast formation in vitro. Biochem Biophys Res Commun. 1991;177:526-531.
41. Quinn JM, Elliott J, Gillespie MT, Martin TJ. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology. 1998;139:4424-4427.
42. Smerdel-Ramoya A, Zanotti S, Canalis E. Connective tissue growth factor (CTGF) transactivates nuclear factor of activated T-cells (NFAT) in cells of the osteoblastic lineage. J Cell Biochem. 2010;110:477-483.
43. Nishida T, Emura K, Kubota S, Lyons KM, Takigawa M. CCN family 2/connective tissue growth factor (CCN2/CTGF) promotes osteoclastogenesis via induction of and interaction with dendritic cell-specific transmembrane protein (DC-STAMP). J Bone Miner Res. 2011;26:351-363.
44. Hirotani H, Tuohy NA, Woo JT, Stern PH, Clipstone NA. The calcineurin/nuclear factor of activatedTcells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J Biol Chem. 2004;279:13984-13992.
45. Knowles HJ, Cleton-Jansen AM, Korsching E, Athanasou NA. Hypoxia- inducible factor regulates osteoclast-mediated bone resorption: role of angiopoietin-like 4. FASEB J. 2010;24:4648-4659.
46. Weir EC, Horowitz MC, Baron R, Centrella M, Kacinski BM, Insogna KL. Macrophage colony-stimulating factor release and receptor expression in bone cells. J Bone Miner Res. 1993;8:1507-1518.
47. Parisi MS, Gazzerro E, Rydziel S, Canalis E. Expression and regulation of CCN genes in murine osteoblasts. Bone. 2006;38:671-677.
48. Ross FP, Teitelbaum SL. αvβ3 And macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev. 2005;208:88-105.
49. Yoshida H, Hayashi S, Kunisada T, et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature. 1990;345:442-444.
50. Smerdel-Ramoya A, Zanotti S, Stadmeyer L, Durant D, Canalis E. Skeletal overexpression of connective tissue growth factor impairs bone formation and causes osteopenia. Endocrinology. 2008;149:4374-4381.
51. Kim K, Lee SH, Ha Kim J, Choi Y, Kim N. NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol. 2008;22:176-185.
52. Imran SA, Brown RE, Wilkinson M. Tissue-specific effects of val-sartan on rstn and fiaf gene expression in the ob/ob mouse. Diab Vasc Dis Res. 2010;7:231-238.
53. Rodriguez-Acebes S, Palacios N, Botella-Carretero JI, et al. Gene expression profiling of subcutaneous adipose tissue in morbid obesity using a focused microarray: distinct expression of cell-cycle- and differentiation- related genes. BMC Med Genomics. 2010;3:61.
54. Robciuc MR, Naukkarinen J, Ortega-Alonso A, et al. Serum angiopoietin-like 4 protein levels and expression in adipose tissue are inversely correlated with obesity in monozygotic twins. J Lipid Res. 2011;52:1575-1582.
55. Lei X, Shi F, Basu D, et al. Proteolytic processing of angiopoietin-like protein 4 by proprotein convertases modulates its inhibitory effects on lipoprotein lipase activity. J Biol Chem. 2011;286:15747-15756.